Morgan Stanley Upgrades Allergen (AGN) to Overweight

(Updated - November 29, 2017 6:56 AM EST)

(updated to add analyst comment)

Morgan Stanley upgraded Allergen (NYSE: AGN) from Equalweight to Overweight with a price target of $200.00.

Analyst David Risinger likes the attractive risk/reward following the recent decline in the equity on the heels of negative news flow and earnings downgrades. The analyst fails see a "major catalyst" on the horizon but feels shares can still outperform.

For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.

Shares of Allergen closed at $171.92 yesterday.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• The Simply Goods Group (SMPL) PT Raised to $15 at UBS Following Q3 Earnings
• FDA approves Padcev plus Keytruda for muscle-invasive bladder cancer